ICICI Prudential Nifty Pharma Index Fund Direct Growth
NAV as on 17-04-2025
₹ 16.3
▲1.2%
1D
Inception Returns
23.6%
/yr
Historical NAV & Returns
Absolute
▲
▼
857 people have invested ₹ 38.8L in ICICI Prudential Nifty Pharma Index Fund Direct Growth in the last three months
About ICICI Prudential Nifty Pharma Index Fund Direct Growth
ICICI Prudential Nifty Pharma Index Fund Direct Growth is an equity fund. This fund was started on 15 December, 2022. The fund is managed by Nishit Patel. The fund could potentially beat inflation in the long-run.
Key Parameters
- ICICI Prudential Nifty Pharma Index Fund Direct Growth has ₹81 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
- The fund has an expense ratio 0.4.
Returns
ICICI Prudential Nifty Pharma Index Fund Direct Growth has given a CAGR return of 23.55% since inception. Over the last 1 year the fund has given a CAGR return of 13.04%.
Holdings
ICICI Prudential Nifty Pharma Index Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Divi's Laboratories Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd
Taxation
As it is a index funds mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of ICICI Prudential Nifty Pharma Index Fund Direct Growth
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 1000.00 and for SIP is INR 1000.00. ICICI Prudential Nifty Pharma Index Fund Direct Growth has no lock in period.
ICICI Prudential Nifty Pharma Index Fund Direct Growth Overview
| Expense ratio | 0.39% |
Benchmark | Nifty Pharma TR INR |
| AUM | ₹81 Cr |
| Inception Date | 15 December, 2022 |
| Min Lumpsum/SIP | ₹1000/₹1000 |
| Exit Load | 0% |
| Lock In | No Lock-in |
TurnOver | 3.54% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Fund Distribution
as on (31-Mar-25)
Large cap
61.8%
Mid cap
29.3%
Small cap
8.3%
Sector Allocation
Health
100%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 6.65% whereas the fund’s underlying benchmark Nifty 50 returns stands at 6.33% as on Mar'25
- This fund outperformed Nifty 50 by 0.32% in Mar'25
- AUM of the fund stands at 80.6 Cr as of Mar'25
- AUM increased by 5.5 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Torrent Pharmaceuticals Ltd's allocation increased from 3.97% to 4.46%
Glenmark Pharmaceuticals Ltd's allocation increased from 2.76% to 3.07%
Mankind Pharma Ltd's allocation increased from 3.41% to 3.62%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 11.09 % to 10.73 %
Divi's Laboratories Ltd's allocation decreased from 9.98 % to 9.7 %
Dr Reddy's Laboratories Ltd's allocation decreased from 10.1 % to 9.23 %
Mid Cap allocation has gone up from 28.9% to 29.3%
Large Cap allocation has gone down from 62.6% to 61.8%
Small Cap allocation has gone down from 8.4% to 8.3%
Cash allocation has gone up from 0.1% to 0.7%
Top Sector in March was Health
Mar'25
Health
100%
Feb'25
Health
100%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 24.74% | -1.1% | |
 Cipla Ltd | 10.73% | 1.4% | |
 Divi's Laboratories Ltd | 9.7% | -1% | |
 Dr Reddy's Laboratories Ltd | 9.23% | -1% | |
 Lupin Ltd | 6.48% | -0.8% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
ICICI Prudential Nifty Pharma Index Fund Direct Growth | 13.04% | - | - | 23.55% |
 Motilal Oswal Nifty Bank Index Fund Direct Growth | 15.05% | 13.86% | 21.46% | 13.14% |
 UTI Nifty 50 Index Fund-Growth Option- Direct | 8.76% | 11.98% | 21.92% | 12.91% |
 SBI Nifty Index Fund Direct Growth | 8.73% | 11.97% | 21.85% | 12.63% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Laurus Labs Ltd | 7% |
 Sun Pharmaceutical Industries Ltd | 0.2% |
Loading...
We are taking more time than usual
Nishit Patel
Fund Manager of ICICI Prudential Nifty Pharma Index Fund Direct Growth, since 15 December 2022
Top funds managed
Fund House
ICICI Prudential Asset Management Company Limited
Total Schemes
Total AUM
₹8.04L Cr
as on 31-Mar-2025
Address
ICICI Prudential Asset Mgmt.Company Limited,3rd Floor, Hallmark Business Plaza,,Sant Dyaneshwar Marg,,Bandra (East)
Phone
+912226428000
Website
investor.helpdesk@hdfcbank.com
ICICI Prudential Nifty Pharma Index Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 23.55% since inception which is more than its category average return of 8.09%
Fund Allocations
This fund has an allocation of 99.32% in Equity, 0% in Debt and 0.68% in Cash related instruments
AUM size ₹81 Cr
This fund has AUM of ₹81 Cr which is less than its category average of ₹ 771 Cr
Expense Ratio 0.39%
This fund has an expense ratio of 0.39% which is less than its category average expense ratio of 0.55%
Frequently Asked Questions for ICICI Prudential Nifty Pharma Index Fund Direct Growth
The current NAV of ICICI Prudential Nifty Pharma Index Fund Direct Growth is ₹16.3 as on 17-Apr-2025.
Existing (Absolute + CAGR) as on 17-Apr-2025.
ICICI Prudential Nifty Pharma Index Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 2.03% | 2.03% |
6 Month Returns | -9.03% | -9.03% |
1 Year Returns | 13.04% | 13.04% |
3 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.39% as on March 2025
₹81 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(24.74%), Cipla Ltd(10.73%), Divi's Laboratories Ltd(9.7%), Dr Reddy's Laboratories Ltd(9.23%), Lupin Ltd(6.48%) as on March 2025
The alpha ratio for the ICICI Prudential Nifty Pharma Index Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ICICI Prudential Nifty Pharma Index Fund Direct Growth | -0.66 | - | - |
As on March 2025
The alpha for ICICI Prudential Nifty Pharma Index Fund Direct Growth is calculated against Nifty Pharma TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Nifty Pharma Index Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ICICI Prudential Nifty Pharma Index Fund Direct Growth | 1 | - | - |
As on March 2025
The Beta for ICICI Prudential Nifty Pharma Index Fund Direct Growth is calculated with Nifty Pharma TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Nifty Pharma Index Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ICICI Prudential Nifty Pharma Index Fund Direct Growth | 0.29 | - | - |
As on March 2025
The sharpe ratio for ICICI Prudential Nifty Pharma Index Fund Direct Growth is calculated with Nifty Pharma TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Nifty Pharma Index Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ICICI Prudential Nifty Pharma Index Fund Direct Growth | 20.24 | - | - |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Nishit Patel is the fund manager of ICICI Prudential Nifty Pharma Index Fund Direct Growth
The Exit load of ICICI Prudential Nifty Pharma Index Fund Direct Growth is 0%